HE4 Levels: Normal Range, Blood Test & What They Mean

If you or someone you know just received a lab report with an "HE4" result on it, the number alone doesn't mean much without context — and search results on the topic swing between dense clinical literature and oversimplified health-site summaries. HE4 (Human Epididymis Protein 4) is a blood-based biomarker used mainly in the evaluation of pelvic masses and ovarian cancer, and understanding what a given value means requires knowing your menopausal status, which assay platform produced the number, and what it's being combined with.

This guide walks through what HE4 is, typical normal ranges, how the blood test is actually performed, what an elevated result does and doesn't mean, and why HE4 is almost always interpreted alongside CA125 rather than on its own.

1. What Is HE4 (Human Epididymis Protein 4)?

HE4, encoded by the WFDC2 gene, is a small secreted glycoprotein belonging to the WAP (whey acidic protein) four-disulfide core (WFDC) family. It was first identified in the epithelium of the distal epididymis, where it was originally thought to function as a protease inhibitor involved in sperm maturation — hence the name "Human Epididymis Protein 4."

HE4's relevance as a tumor marker comes from tissue-expression studies showing it is strongly overexpressed in the most common types of epithelial ovarian cancer: approximately 93% of serous ovarian carcinomas, 100% of endometrioid ovarian carcinomas, and 50% of clear cell (non-mucinous) ovarian carcinomas show HE4 overexpression. Because these tumor cells actively secrete HE4 into the bloodstream, a rise in tumor burden translates into a measurable rise in serum HE4 concentration — the basis for using it as a blood test.

2. HE4 Normal Range by Menopausal Status

Unlike some biomarkers with a single universal cutoff, HE4 reference ranges differ by menopausal status, because HE4 rises gradually with age independent of any disease process. Values also differ somewhat between assay manufacturers (ELISA, CLIA, and ECLIA platforms are not fully interchangeable), so the exact number that counts as "normal" should always come from the specific lab that ran your test.

These figures represent commonly cited reference values from widely used automated immunoassay platforms and are provided for general orientation only — they are not a substitute for the reference range printed on your own lab report. A result modestly above the upper limit is not automatically abnormal; trend over time and clinical context matter more than a single value near the cutoff.

3. How the HE4 Blood Test Works

The HE4 test is a straightforward blood draw with no special preparation required:

• Sample type: A standard venous blood draw is collected and processed into serum; no fasting is required.
• Method: The sample is run on an automated immunoassay platform using a double-antibody sandwich format — a capture antibody binds HE4 in the sample, and a labeled detection antibody (commonly HRP-conjugated for ELISA, or a chemiluminescent label for CLIA/ECLIA) generates a signal proportional to the HE4 concentration.
• Turnaround: Results are typically available within 1–3 business days, depending on the laboratory.
• When it's ordered: Most commonly alongside CA125 as part of a pelvic mass evaluation, or during follow-up surveillance for women previously treated for ovarian cancer to help detect recurrence.

Because HE4 is almost never ordered as a stand-alone screening test in women without symptoms or an identified pelvic mass, receiving an HE4 result usually means a physician is already investigating a specific clinical question — most often the nature of a pelvic mass found on examination or imaging.

4. What Level of HE4 Indicates Cancer Risk?

This is the question most people searching for HE4 information actually want answered, and the honest answer is: there is no single HE4 number that, by itself, confirms or rules out cancer. HE4 is a risk-stratification and monitoring marker, not a stand-alone diagnostic test.

What an elevated HE4 result typically triggers is further evaluation, not an immediate diagnosis:

• A markedly elevated value — particularly in a postmenopausal woman, where benign causes of elevation are less common — raises clinical suspicion.
• A value that continues to rise on repeat testing is more concerning than a single borderline result.
• Elevated HE4 typically prompts transvaginal ultrasound imaging and, depending on findings, referral to a gynecologic oncologist.
• A definitive diagnosis always requires imaging plus tissue evaluation (biopsy or surgical pathology) — blood markers alone cannot diagnose cancer.

In published comparative studies, HE4 alone has demonstrated approximately 82.7% sensitivity for early-stage ovarian cancer detection and approximately 99% specificity — meaning the false-positive rate in healthy women is roughly 1%. This is why an elevated HE4 result carries real clinical weight even though it is not diagnostic on its own.

5. HE4 vs. CA125: Why Doctors Use Both (ROMA Score)

CA125 has long been the standard biomarker for ovarian cancer, but it has real limitations: approximately 50% of Stage I ovarian cancer patients do not show elevated CA125, and CA125 specificity is low (approximately 20%) because many benign gynecological conditions — fibroids, endometriosis, and pelvic inflammatory disease, particularly in premenopausal women — also raise CA125.

Because HE4's strengths (high specificity) and CA125's strengths (established track record, especially post-diagnosis monitoring) are complementary, most clinical protocols use both markers together — sometimes combined into a formal Risk of Ovarian Malignancy Algorithm (ROMA) score, which factors in HE4, CA125, and menopausal status to generate a percentage risk estimate for epithelial ovarian cancer. Combining the two markers reduces false-negative results by an estimated 30–50% compared with using either marker alone, which is particularly valuable for catching early-stage disease that a single marker might miss.

6. Other Causes of Elevated HE4 (Non-Cancer)

An elevated HE4 result is not proof of ovarian cancer. Several non-malignant factors can raise HE4 levels:

• Age and menopause: HE4 rises gradually and naturally with age, independent of disease — this is why reference ranges are menopause-adjusted.
• Reduced kidney function: HE4 is partly cleared by the kidneys, so impaired renal function can elevate serum HE4 levels without any underlying malignancy.
• Smoking: Smoking has been associated with modestly higher HE4 concentrations in some studies.
• Other epithelial cancers: HE4 is not exclusively ovarian — it can also be elevated in some endometrial cancers and certain lung adenocarcinomas, since these tissues can share HE4 expression.

This is exactly why a physician interprets an HE4 result in the context of age, menopausal status, kidney function, imaging findings, and — most often — the corresponding CA125 result, rather than reacting to a single elevated number in isolation.

7. Frequently Asked Questions About HE4

What is a normal HE4 level?

HE4 reference ranges depend on menopausal status and the specific immunoassay platform used, so there is no single universal number. Many clinical laboratories report an upper reference limit of approximately 70 pmol/L for premenopausal women and approximately 140 pmol/L for postmenopausal women, reflecting the fact that HE4 rises naturally with age independent of any disease. Always interpret an individual result against the reference range printed on that specific lab report, since assay platforms are not fully interchangeable.

How is the HE4 blood test performed?

The HE4 test uses a standard venous blood draw to collect a serum sample; no fasting is required. The sample is run on an automated immunoassay platform (ELISA, CLIA, or ECLIA) using a sandwich format with a capture antibody and an enzyme- or label-conjugated detection antibody, producing a quantitative result in pmol/L or U/mL depending on the assay. HE4 is frequently ordered alongside CA125 as part of a pelvic mass workup or during post-treatment surveillance for ovarian cancer, with results typically available in 1-3 business days.

What level of HE4 indicates cancer?

There is no single HE4 concentration that, by itself, confirms or rules out cancer. HE4 is a risk-stratification and monitoring marker, not a stand-alone diagnostic test. A markedly elevated result — especially in a postmenopausal woman, or a result that keeps rising on repeat testing — raises clinical suspicion and typically prompts imaging (transvaginal ultrasound) and specialist referral. HE4 is most often used together with CA125 and menopausal status in a combined risk score (such as ROMA) rather than interpreted as a single cutoff, and a definitive diagnosis always requires imaging plus tissue evaluation.

Is HE4 a reliable tumor marker on its own?

Used alone, HE4 has been reported to reach approximately 82.7% sensitivity for early-stage ovarian cancer detection and approximately 99% specificity, both notably better than CA125 alone (approximately 45.9% sensitivity and approximately 20% specificity). However, HE4 is generally used as part of a combined evaluation rather than in isolation — pairing HE4 with CA125 raises sensitivity to approximately 92% and reduces false-negative results by 30-50% compared with either marker alone.

Can HE4 be elevated without ovarian cancer?

Yes. HE4 rises with normal aging and after menopause independent of any tumor, and it is partly cleared by the kidneys, so reduced kidney function can raise HE4 levels. Smoking has also been associated with modestly higher HE4. HE4 additionally reflects other epithelial tumors that share HE4 expression, such as endometrial and some lung adenocarcinomas, so an elevated result is a prompt for further clinical evaluation rather than a specific diagnosis on its own.

Does Sekbio supply HE4 antibody and antigen raw materials for ELISA kit development?

Yes. Sekbio manufactures a matched HE4 capture antibody, HRP-conjugated detection antibody, and recombinant HE4 antigen under ISO 13485 for ovarian cancer ELISA sandwich kit development, along with the equivalent CA125 Antibody Pair for dual-marker panels. Visit our Platforms page for antibody development and custom antigen expression services.

8. Summary

Key takeaways on HE4 levels and testing:

• HE4 reference ranges are menopause-adjusted: commonly cited upper limits are approximately 70 pmol/L premenopausal and approximately 140 pmol/L postmenopausal, but always defer to your own lab's reported range.
• The blood test itself is simple: a routine serum draw processed on an ELISA, CLIA, or ECLIA immunoassay platform, usually ordered together with CA125.
• No single number equals a cancer diagnosis: elevated or rising HE4 raises clinical suspicion and prompts imaging and specialist evaluation — it does not diagnose cancer by itself.
• HE4 and CA125 are complementary: combining both markers raises sensitivity to approximately 92% and reduces false negatives by 30-50% compared with either marker alone.
• Elevated HE4 has non-cancer causes too: age, menopause, reduced kidney function, and smoking can all raise HE4 without malignancy.

For IVD developers and diagnostic kit manufacturers building assays around this biomarker pair, Sekbio supplies the matched HE4 antibody and antigen panel — capture antibody, HRP-conjugated detection antibody, and recombinant antigen — manufactured under ISO 13485 for ELISA sandwich kit development, alongside the complementary CA125 antibody pair for combined dual-marker ovarian cancer panels.